The landscape of alopecia areata management is evolving rapidly within the Asia-Pacific region. Recently, a modified Delphi expert panel consisting of 18 dermatologists from eight countries, including India, provided updated recommendations. These guidelines help clinicians navigate the clinical heterogeneity of the disease. Moreover, they address the significant quality-of-life impact that hair loss imposes on patients and their families.

Essential Diagnostic Tools for Alopecia Areata Management

The panel emphasizes that trichoscopy is an essential tool for both diagnosis and ongoing monitoring. Specifically, clinicians should use it to identify pathognomonic markers such as black dots, yellow dots, and tapering hairs. However, experts suggest that skin biopsy is not necessary for every patient. Instead, doctors should reserve this procedure for cases where the underlying cause of hair loss remains unclear or diagnostic uncertainty persists.

Classification and Therapeutic Strategies

Consistency in staging is vital for effective treatment planning. Consequently, the panel defines moderate alopecia areata as 21% to 49% scalp involvement. They classify cases with 50% or more hair loss as severe. This distinction is critical because it dictates the choice between topical and systemic interventions. For instance, topical corticosteroids remain the primary recommendation for pediatric patients. Furthermore, the consensus incorporates recently approved systemic treatments, providing a roadmap for modern clinical practice in India and across the APAC region.

Frequently Asked Questions

How do the new guidelines classify disease severity?

The Asia-Pacific consensus defines moderate disease as 21% to 49% hair loss. Severe cases involve 50% or more of the scalp.

Is a skin biopsy required for a diagnosis?

No, a biopsy is not routine. Clinicians primarily use trichoscopy for diagnosis and only use biopsy when the cause of hair loss is uncertain.

What is recommended for children with alopecia areata?

The panel suggests topical corticosteroids as the preferred initial treatment for pediatric patients.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare. Always seek the advice of a qualified health provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Sinclair R et al. Epidemiology, Diagnosis and Management of Alopecia Areata: An Asia-Pacific Modified Delphi Expert Panel Recommendations. Int J Dermatol. 2026 Feb 16. doi: 10.1111/ijd.70335. PMID: 41699409.


2. Sardana K, Bathula S, Khurana A. Which is the ideal JAK inhibitor for alopecia areata — baricitinib, tofacitinib, ritlecitinib or ifidancitinib — revisiting the immunomechanisms of the JAK pathway. Indian Dermatol Online J. 2023; 14(4): 465–474.


3. Ju HJ, Shin JW, Choi JW, et al. Korean Consensus Criteria for the Severity Classification of Alopecia Areata. Ann Dermatol. 2020;32(2):115-121.